Today's Rundown Bristol-Myers' CAR-T poised for FDA filing after banishing lymphoma in 53% of patients AstraZeneca's Calquence posts sky-high survival numbers in previously untreated CLL Eli Lilly plots 'ambitious' cancer program after sharing early BTK data AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL J&J's anti-BCMA CAR-T clears multiple myeloma in 69% of patients in phase 1 Gilead Sciences touts 'astounding' Yescarta survival results at 3 years Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts BeiGene, eyeing Imbruvica's CLL share, touts more early Brukinsa data Takeda details Ninlaro's miss in AL amyloidosis Novartis trumpets hospitalization data for newly minted sickle cell drug Adakveo Featured Story | | | Saturday, December 7, 2019 In a newly unveiled study, Bristol-Myers Squibb’s CAR-T therapy banished tumors in more than half of relapsed blood cancer patients and shrank tumors in nearly three-quarters of them. The treatment, picked up in the company’s $74 billion Celgene buyout, could help patients with large B-cell lymphomas whose disease has worsened despite trying other treatments. |
|
|---|
|
Top Stories Sunday, December 8, 2019 ORLANDO—Over the last couple of weeks, regulators in the U.S., Canada and Australia have all green-lighted AstraZeneca’s Calquence in newly diagnosed chronic lymphocytic leukemia patients. And Saturday, the company unveiled more of the data that convinced them to dole out those approvals. Sunday, December 8, 2019 Eli Lilly shared early clinical data on the BTK inhibitor it acquired with Loxo Oncology—and the numbers are strong enough to prompt some action. Most of the heavily pretreated trial patients responded to the drug, emboldening Lilly to outline “an ambitious comprehensive development program.” Sunday, December 8, 2019 ORLANDO—AbbVie and Roche have been fielding their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep chronic lymphocytic leukemia from returning after therapy ends. The companies now think they have some compelling answers. Saturday, December 7, 2019 Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study. The treatment, which also shrank tumors in all 29 of the patients, kept cancer at bay in 93% of patients six months after dosing. Sunday, December 8, 2019 ORLANDO—How long can a single infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead Sciences showed Saturday. Nearly half of patients treated with Yescarta more than three years ago—47%—were still alive at a median follow-up of 39.1 months. Monday, December 9, 2019 Roche has rolled out new data showing mosunetuzumab can trigger complete responses in a tough group—lymphoma patients failed by CAR-Ts and other drugs. The phase 1/2b linked the bispecific antibody to long-lasting responses in a significant minority of hard-to-treat non-Hodgkin lymphoma patients. Sunday, December 8, 2019 ORLANDO—BeiGene only recently won its first approval for Brukinsa with a nod in mantle cell lymphoma. But it’s already pushing to join the CLL field, and Sunday it rolled out new response-rate data that could help it toward that goal. Monday, December 9, 2019 Back in June, Takeda scrapped a Ninlaro trial in the rare disease light-chain (AL) amyloidosis. Saturday, it shared the data behind the decision—results execs say they’re excited to get into the public domain. Sunday, December 8, 2019 With a brand-new approval for targeted sickle cell disease therapy Adakveo under its belt, Novartis showed off an analysis Sunday demonstrating the drug could cut down on patient hospitalizations by 40%. Resources Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Clarivate Analytics Get your copy of the Q2 2019 Life Sciences M&A notes and trends to understand the mergers and acquisitions (M&A) activity in the life sciences sector which drove 136 new M&A deals and provides a forward look to 2020 activity ahead. Sponsored by: Thermo Fisher Scientific Are you facing costly delays in your API scale-up? Sponsored by: Evidera Increasing global adoption of EMRs at clinical sites has prompted interest in using sites’ EMRs systematically for observational studies. Learn about the benefits and challenges in this white paper. Read now. Sponsored by: Roche and IQVIA This global landscape study identifies and assesses innovative funding models for cancer and other high-cost chronic NCDs across Africa, Asia, Europe, Latin America and Middle East. The study aims to enable readers to better understand the possibilities that innovative funding models bring to bridge the current and future funding gap, while stressing the key success factors that enable sustainability and success such as stakeholder collaboration. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks. Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Asia-Pacific Healthcare Compliance Certificate Program March 9-12, 2020 FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2020 January 14, 2020 | The Fairmont Hotel | San Francisco, CA Middle East Healthcare Compliance Certificate Program March 23-26, 2020 ThinkLive2019 Explore these articles and videos from this year’s ThinkLive Summit and cover some of the industry’s most pressing topics, from supporting biosimilars to drug pricing policy. | 